MHRA Borderline Guidance MHRA guidance updated on 2 July 2026 explains that classification can consider pharmacological properties, explicit and implied claims, intended purpose, packaging, websites, social-media content and customer reviews
We examine market insights, practical strategies, and regulatory considerations to ensure research integrity
When to use it: Oral Liposomal BPC + KPV is appropriate for exclusive practitioner-directed use in adult clients with ongoing concerns related to compromised gut barrier function, gastrointestinal conditions, skin conditions, and immune and inflammatory dysfunction
Antioxidant Activity: It neutralizes free radicals, unstable molecules that can damage cells and accelerate aging, thus protecting tissues from oxidative stress
It helps with brain work and making red blood cells